Forte Biosciences
Tracked across 1 events · 7 articles · First seen Apr 08, 2026 · Last active Apr 09, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Forte Biosciences announced the pricing of a public offering of 5,709,936 shares of its common stock at $26.27 per share, expecting to raise approximately $150 million. This capital infusion is intended for working capital, general corporate purposes, and funding clinical development of its product candidate FB102 and other research activities.
Apr 08, 2026 · 7 articles
100
Forte Biosciences Commenced and priced a public offering of common stockForte Biosciences Prices...
80
Forte Biosciences Granted underwriters a 30-day option to purchase additional sharesForte Biosciences Prices...
70
Guggenheim Securities Acted as book-running manager for the offering Forte BiosciencesForte Biosciences Prices...
60
Barclays Acted as joint book-running manager for the offering Forte BiosciencesForte Biosciences Prices...
Guggenheim Securities
client
↔
Forte Biosciences
Forte Biosciences is a client of Guggenheim Securities for its public offering.
NEWSDESK
Track Forte Biosciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard